Ourania Tatsis - Feb 24, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Reg. & Quality Off.
Signature
/s/ Joy Liu, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 24, 2023
Transactions value $
-$1,058,177
Form type
4
Date filed
2/28/2023, 04:11 PM
Previous filing
Feb 22, 2023
Next filing
Aug 14, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$956K -3.31K -5.47% $289.12 57.2K Feb 24, 2023 Direct
transaction VRTX Common Stock Sale -$81.3K -283 -0.5% $287.20 56.9K Feb 27, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$14.7K -51 -0.09% $288.33 56.8K Feb 27, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$5.79K -20 -0.04% $289.29 56.8K Feb 27, 2023 Direct F1, F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $287.20 (range $286.71 to $287.60).
F4 Open market sales reported on this line occurred at a weighted average price of $288.33 (range $287.82 to $288.74).
F5 Open market sales reported on this line occurred at a weighted average price of $289.29 (range $289.17 to $289.40).